The proposed acquisition would hand Servier a couple experimental drugs in human testing as well as Ojemda, an approved ...

The regimen’s clearance in early multiple myeloma was the third approval under the agency’s controversial “national priority” voucher program and issued only 55 days after the review began.

An amylin-targeting medicine at the center of the companies’ multibillion-dollar alliance spurred less weight loss than ...

The clearance in China comes weeks after Pfizer acquired rights to the therapy. Elsewhere, Alnylam is looking for “novel” cardiovascular targets and investors sold off Helus shares.

Atavistik Bio is using the cash to develop “allosteric” medicines it believes can precisely impact on diseases like myelofibrosis and the blood condition HHT.

Candid, which is making bispecifics for immune diseases, has also raised $505 million in a private financing for the newly ...

Announced days before a trial, the deal settles a longstanding dispute and avoids what one analyst called a “worst-case scenario” financially for Moderna.

A month after Amgen gave up on rocatinlimab — which was once seen as a threat to Dupixent — new findings have linked the drug ...

The AI drug discovery specialist is the fifth biotechnology company to go public in February and priced the sector’s largest ...

The agency acted after reviewing mouse data submitted in 2024, making the timing of the new pause “confusing,” one analyst wrote.

The detection of certain cardiac issues in a study of healthy volunteers led Aardvark to pause a Phase 3 trial only months before an expected data readout.

Liver-related side effects have led some analysts to question fenebrutinib’s prospects, even though the drug has now cleared ...